Letters to the Editor

Letters to the Editor

Workplace Violence

In our March 2018 issue, ASH Clinical News Associate Editor Alice Ma, MD, recounted an unnerving experience with a threatening patient in “Not What...

Doing No Harm Versus the Right to Bear Arms

In our December 2017 issue, “Gun Violence: A Public Health Crisis,” we spoke with experts about the complexities of treating gun control as a...

CROs: A Universal Problem

Contract research organizations (CROs), which are used by much of the pharmaceutical industry to outsource research regulatory requirements, should be the epitomes of high-quality...

A Thought-Provoking Question

In our September issue, Elisabeth M. Battinelli, MD, PhD, responded to a colleague seeking advice on managing a patient who developed deep-vein thrombosis (DVT)...

Can’t We All Get Along?

In his August 2017 editorial (“Musing on Medical Marvels”), Keith Stewart, MBChB, MBA, recounted the amazing innovations in cancer treatment in the past 20...

CROs and Cons

In his June 2017 Editor’s Corner (“Contract Research Agonizations”), ASH Clinical News’ Editor-in-Chief Mikkael Sekeres, MD, MS, called for an end to the bureaucratic...

Advocating for a Return to Common Sense in Clinical Research

In his June 2017 Editor’s  Corner (“Contract Research Agonizations”), ASH Clinical News’ Editor-in-Chief Mikkael Sekeres, MD, MS, called for an end to the bureaucratic...

Impatient Practicum

In his April 2017 Editor’s Corner, Editor-in-Chief Mikkael Sekeres issued his annual missive to the American Board of Internal Medicine (“Letter from a Cleveland...

Not-So-NICE One

In December 2016, we published an Online Exclusive item reporting on the United Kingdom’s National Institute for Health and Care Excellence’s (NICE) review of...

Another Clinical Research Secret

In the December 2016 Editor’s Corner (“So You Say You Want to Be a Clinical Researcher?”), Mikkael A. Sekeres, MD, MS, offered advice for...
Advertisement

Current Issue

May 2018, Volume 4, Issue 6

This issue features a look at the hidden costs of importing lower-cost drugs, the optimal hemophilia treatment, the limits of genetic testing, and more.